685 related articles for article (PubMed ID: 25620012)
1. Self-amplifying mRNA vaccines.
Brito LA; Kommareddy S; Maione D; Uematsu Y; Giovani C; Berlanda Scorza F; Otten GR; Yu D; Mandl CW; Mason PW; Dormitzer PR; Ulmer JB; Geall AJ
Adv Genet; 2015; 89():179-233. PubMed ID: 25620012
[TBL] [Abstract][Full Text] [Related]
2. Nucleic acid vaccines: prospects for non-viral delivery of mRNA vaccines.
Deering RP; Kommareddy S; Ulmer JB; Brito LA; Geall AJ
Expert Opin Drug Deliv; 2014 Jun; 11(6):885-99. PubMed ID: 24665982
[TBL] [Abstract][Full Text] [Related]
3. Enhanced Delivery and Potency of Self-Amplifying mRNA Vaccines by Electroporation in Situ.
Cu Y; Broderick KE; Banerjee K; Hickman J; Otten G; Barnett S; Kichaev G; Sardesai NY; Ulmer JB; Geall A
Vaccines (Basel); 2013 Aug; 1(3):367-83. PubMed ID: 26344119
[TBL] [Abstract][Full Text] [Related]
4. mRNA vaccine delivery using lipid nanoparticles.
Reichmuth AM; Oberli MA; Jaklenec A; Langer R; Blankschtein D
Ther Deliv; 2016; 7(5):319-34. PubMed ID: 27075952
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and protective efficacy induced by self-amplifying mRNA vaccines encoding bacterial antigens.
Maruggi G; Chiarot E; Giovani C; Buccato S; Bonacci S; Frigimelica E; Margarit I; Geall A; Bensi G; Maione D
Vaccine; 2017 Jan; 35(2):361-368. PubMed ID: 27939014
[TBL] [Abstract][Full Text] [Related]
6. Nonviral delivery of self-amplifying RNA vaccines.
Geall AJ; Verma A; Otten GR; Shaw CA; Hekele A; Banerjee K; Cu Y; Beard CW; Brito LA; Krucker T; O'Hagan DT; Singh M; Mason PW; Valiante NM; Dormitzer PR; Barnett SW; Rappuoli R; Ulmer JB; Mandl CW
Proc Natl Acad Sci U S A; 2012 Sep; 109(36):14604-9. PubMed ID: 22908294
[TBL] [Abstract][Full Text] [Related]
7. A cationic nanoemulsion for the delivery of next-generation RNA vaccines.
Brito LA; Chan M; Shaw CA; Hekele A; Carsillo T; Schaefer M; Archer J; Seubert A; Otten GR; Beard CW; Dey AK; Lilja A; Valiante NM; Mason PW; Mandl CW; Barnett SW; Dormitzer PR; Ulmer JB; Singh M; O'Hagan DT; Geall AJ
Mol Ther; 2014 Dec; 22(12):2118-2129. PubMed ID: 25027661
[TBL] [Abstract][Full Text] [Related]
8. Self-amplifying mRNA-Based Vaccine Technology and Its Mode of Action.
Maruggi G; Ulmer JB; Rappuoli R; Yu D
Curr Top Microbiol Immunol; 2022; 440():31-70. PubMed ID: 33861374
[TBL] [Abstract][Full Text] [Related]
9. mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases.
Maruggi G; Zhang C; Li J; Ulmer JB; Yu D
Mol Ther; 2019 Apr; 27(4):757-772. PubMed ID: 30803823
[TBL] [Abstract][Full Text] [Related]
10. Innovative Strategies to Enhance mRNA Vaccine Delivery and Effectiveness: Mechanisms and Future Outlook.
Verma A; Awasthi A
Curr Pharm Des; 2024; 30(14):1049-1059. PubMed ID: 38551046
[TBL] [Abstract][Full Text] [Related]
11. The role of nanoparticle format and route of administration on self-amplifying mRNA vaccine potency.
Anderluzzi G; Lou G; Woods S; Schmidt ST; Gallorini S; Brazzoli M; Johnson R; Roberts CW; O'Hagan DT; Baudner BC; Perrie Y
J Control Release; 2022 Feb; 342():388-399. PubMed ID: 34896446
[TBL] [Abstract][Full Text] [Related]
12. Advanced nanoscale delivery systems for mRNA-based vaccines.
Mobasher M; Ansari R; Castejon AM; Barar J; Omidi Y
Biochim Biophys Acta Gen Subj; 2024 Mar; 1868(3):130558. PubMed ID: 38185238
[TBL] [Abstract][Full Text] [Related]
13. Induction of an IFN-Mediated Antiviral Response by a Self-Amplifying RNA Vaccine: Implications for Vaccine Design.
Pepini T; Pulichino AM; Carsillo T; Carlson AL; Sari-Sarraf F; Ramsauer K; Debasitis JC; Maruggi G; Otten GR; Geall AJ; Yu D; Ulmer JB; Iavarone C
J Immunol; 2017 May; 198(10):4012-4024. PubMed ID: 28416600
[TBL] [Abstract][Full Text] [Related]
14. Development of nucleic acid vaccines: use of self-amplifying RNA in lipid nanoparticles.
Rodríguez-Gascón A; del Pozo-Rodríguez A; Solinís MÁ
Int J Nanomedicine; 2014; 9():1833-43. PubMed ID: 24748793
[TBL] [Abstract][Full Text] [Related]
15. A new generation of vaccines based on alphavirus self-amplifying RNA.
Ballesteros-Briones MC; Silva-Pilipich N; Herrador-Cañete G; Vanrell L; Smerdou C
Curr Opin Virol; 2020 Oct; 44():145-153. PubMed ID: 32898764
[TBL] [Abstract][Full Text] [Related]
16. Vaccines 'on demand': science fiction or a future reality.
Ulmer JB; Mansoura MK; Geall AJ
Expert Opin Drug Discov; 2015 Feb; 10(2):101-6. PubMed ID: 25582273
[TBL] [Abstract][Full Text] [Related]
17. Mechanism of action of mRNA-based vaccines.
Iavarone C; O'hagan DT; Yu D; Delahaye NF; Ulmer JB
Expert Rev Vaccines; 2017 Sep; 16(9):871-881. PubMed ID: 28701102
[TBL] [Abstract][Full Text] [Related]
18. Challenges and advances towards the rational design of mRNA vaccines.
Pollard C; De Koker S; Saelens X; Vanham G; Grooten J
Trends Mol Med; 2013 Dec; 19(12):705-13. PubMed ID: 24138818
[TBL] [Abstract][Full Text] [Related]
19. [New Hopes in Vaccine Technology: mRNA Vaccines].
Yılmaz E
Mikrobiyol Bul; 2021 Apr; 55(2):265-284. PubMed ID: 33882657
[TBL] [Abstract][Full Text] [Related]
20. Nonclinical Safety Assessment of Lipid Nanoparticle-and Emulsion-Based Self-Amplifying mRNA Vaccines in Rats.
Donahue DA; Ballesteros C; Maruggi G; Glover C; Ringenberg MA; Marquis M; Ben Abdeljelil N; Ashraf A; Rodriguez LA; Stokes AH
Int J Toxicol; 2023; 42(1):37-49. PubMed ID: 36472205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
